Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Long-term follow-up of bone density in women with primary ovarian insufficiency

Full text
Author(s):
Benetti-Pinto, Cristina Laguna [1] ; Ferreira, Valeska B. [2] ; Yela, Daniela A. [1]
Total Authors: 3
Affiliation:
[1] Univ Estadual Campinas, Sch Med Sci, Dept Gynecol & Obstet, Campinas, SP - Brazil
[2] Univ Estadual Campinas, Sch Med Sci, Campinas, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY; v. 22, n. 9, p. 946-949, SEP 2015.
Web of Science Citations: 5
Abstract

Objective: This study aims to analyze long-term variation in bone mineral density among young women with primary ovarian insufficiency. Methods: A cohort study evaluated bone mineral density in 72 women with primary ovarian insufficiency who were receiving estrogen + progestogen therapy. Bone mineral density was evaluated every 2 years for 8 years. Results: The women were young, with a mean (SD) age of 34.1 (6.7) years and had a bone density measurement at baseline. The mean (SD) time between the last menstruation and the beginning of hormone treatment was 2.9 (4.2) years. The initial mean (SD) bone mineral density was 1.03 (0.17) and 0.91 (0.16) g/cm(2) for the lumbar spine and femoral neck, respectively. The mean (SD) T score was -1.03 (1.39) and -0.29 (1.09) for the lumbar spine and femoral neck, respectively. Bone mineral density measurements after a follow-up period of 2, 4, 6, and 8 years did not differ from bone mineral density at baseline. Osteopenia and osteoporosis were observed at the lumbar spine and femoral neck in 46% and 25% of women at the time of diagnosis, with no difference in the percentage of affected women across time. Conclusions: Although women with primary ovarian insufficiency who are receiving estrogen + progestogen therapy maintain stable bone mass throughout an 8-year follow-up period, this treatment is not sufficient to decrease the number of women who experience some level of low bone density. Therapeutic regimens should be reviewed, probably with resumption of discussions about the need for other therapeutic strategies. (AU)

FAPESP's process: 12/23669-0 - Analysis of clinical, laboratory and metabolic women with premature ovarian failure
Grantee:Valeska Beatrice Ferreira
Support Opportunities: Scholarships in Brazil - Scientific Initiation